TriangleViPOR Combination (NCT03223610)
ViPOR Combination trial for Relapsed/Refractory B-Cell Lymphoma (NCT03223610). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for B cell lymphoma that has returned or not improved after treatment, in adults 18 and older.
The idea: combine five drugs. ViPOR is a combination that includes venetoclax and ibrutinib. In the first part, drugs are added in steps to study safety and find a dose. Later patients all receive the full combination for six cycles.
The study began in 2018 and plans 155 patients. At the National Institutes of Health Clinical Center in Bethesda, Christopher Melani leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.